Feasibility of ablation as an alternative to surgical metastasectomy in patients with unresectable sarcoma pulmonary metastases

Interact Cardiovasc Thorac Surg. 2009 Dec;9(6):1051-3. doi: 10.1510/icvts.2009.218743. Epub 2009 Sep 18.

Abstract

Percutaneous radiofrequency ablation (RFA) is an alternate treatment modality for pulmonary metastasis in non-surgical candidates. Four patients not suitable for surgery underwent percutaneous RFA for pulmonary metastases from leiomyosarcoma. Success of RFA was assessed with computed tomography (CT). The median length from the radiographic diagnosis of metastatic pulmonary disease (CT-scan) from the primary tumor diagnosis was 67.0 months with a range of 15.0-81.0 months. The median disease free interval following RFA was 19.0 months with a range of 4.0-35.0 months. Three of four patients underwent the procedure uneventfully. RFA is a safe and minimally invasive intervention in non-surgical candidates with sarcoma pulmonary metastases.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Catheter Ablation* / adverse effects
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Feasibility Studies
  • Female
  • Humans
  • Leiomyosarcoma / diagnostic imaging
  • Leiomyosarcoma / mortality
  • Leiomyosarcoma / secondary
  • Leiomyosarcoma / surgery*
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / mortality
  • Lung Neoplasms / secondary
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome